MA48154A1 - Oligonucleotide compositions and their preparation methods - Google Patents
Oligonucleotide compositions and their preparation methodsInfo
- Publication number
- MA48154A1 MA48154A1 MA48154A MA48154A MA48154A1 MA 48154 A1 MA48154 A1 MA 48154A1 MA 48154 A MA48154 A MA 48154A MA 48154 A MA48154 A MA 48154A MA 48154 A1 MA48154 A1 MA 48154A1
- Authority
- MA
- Morocco
- Prior art keywords
- free
- bond
- amino group
- dinucleotide
- protected
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 230000008878 coupling Effects 0.000 abstract 2
- 238000010168 coupling process Methods 0.000 abstract 2
- 238000005859 coupling reaction Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000002777 nucleoside Substances 0.000 abstract 2
- 239000007790 solid phase Substances 0.000 abstract 2
- 238000010511 deprotection reaction Methods 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000012011 nucleophilic catalyst Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 abstract 1
- 238000005987 sulfurization reaction Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente divulgation concerne un procédé en phase solide pour préparer des oligonucléotides par l'intermédiaire de cycles de couplages séquentiels comprenant au moins un couplage d'un sous-motif dimère dinucléotidique à un groupe 3'-terminal libre d'une chaîne en cours d'allongement. Les oligonucléotides comprennent au moins deux sous-motifs nucléosidiques reliés par une liaison n3'? P5'phosphoramidate. Le procédé peut comprendre les étapes de (a) déprotection du groupe 3'-amino protégé d'un nucléoside terminal immobilisé sur un support en phase solide, ladite déprotection formant un groupe 3'-amino libre ; (b) mise en contact du groupe 3'-amino libre avec un dimère 3'-amino protégé-dinucléotide-5'-phosphoramidite en présence d'un catalyseur nucléophile pour former une liaison internucléosidique n3'? P5' ; et (c) oxydation (p. Ex., sulfuration) de la liaison. Les compositions produites par les présents procédés peuvent contenir une quantité réduite d'un ou de plusieurs produits oligonucléotidiques (n-x). Des compositions pharmaceutiques contenant les présentes compositions d'oligonucléotides sont en outre décrites.The present disclosure relates to a solid phase process for preparing oligonucleotides via rounds of sequential coupling comprising at least one coupling of a dinucleotide dimeric subunit to a free 3'-terminal group of a chain in progress. 'elongation. The oligonucleotides comprise at least two nucleoside subunits linked by an n3 ′ bond. P5'phosphoramidate. The method may comprise the steps of (a) deprotecting the protected 3'-amino group of a terminal nucleoside immobilized on a solid phase support, said deprotection forming a free 3'-amino group; (b) contacting the free 3'-amino group with a protected 3'-amino-dinucleotide-5'-phosphoramidite dimer in the presence of a nucleophilic catalyst to form an n3 'internucleoside bond? P5 '; and (c) oxidation (eg, sulfurization) of the bond. Compositions produced by the present methods may contain a reduced amount of one or more oligonucleotide products (n-x). Pharmaceutical compositions containing the present oligonucleotide compositions are further disclosed.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987396P | 2014-05-01 | 2014-05-01 | |
| PCT/US2015/028327 WO2015168310A1 (en) | 2014-05-01 | 2015-04-29 | Oligonucleotide compositions and methods of making the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA48154A1 true MA48154A1 (en) | 2021-09-30 |
| MA48154B1 MA48154B1 (en) | 2022-05-31 |
Family
ID=58700032
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA48154A MA48154B1 (en) | 2014-05-01 | 2015-04-29 | Oligonucleotide compositions and methods for their preparation |
| MA39398A MA39398A1 (en) | 2014-05-01 | 2015-04-29 | Oligonucleotide compositions and methods for their preparation |
| MA59673A MA59673A1 (en) | 2014-05-01 | 2016-10-20 | Oligonucleotide compositions and methods of preparing them |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39398A MA39398A1 (en) | 2014-05-01 | 2015-04-29 | Oligonucleotide compositions and methods for their preparation |
| MA59673A MA59673A1 (en) | 2014-05-01 | 2016-10-20 | Oligonucleotide compositions and methods of preparing them |
Country Status (2)
| Country | Link |
|---|---|
| AR (2) | AR100235A1 (en) |
| MA (3) | MA48154B1 (en) |
-
2015
- 2015-04-29 MA MA48154A patent/MA48154B1/en unknown
- 2015-04-29 MA MA39398A patent/MA39398A1/en unknown
- 2015-04-29 AR ARP150101301A patent/AR100235A1/en active IP Right Grant
-
2016
- 2016-10-20 MA MA59673A patent/MA59673A1/en unknown
-
2020
- 2020-04-06 AR ARP200100967A patent/AR118606A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR118606A2 (en) | 2021-10-20 |
| MA39398A1 (en) | 2019-03-29 |
| MA59673A1 (en) | 2023-04-28 |
| AR100235A1 (en) | 2016-09-21 |
| MA48154B1 (en) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA63525B1 (en) | Oligonucleotide compositions and methods of preparation thereof | |
| EP4361283A3 (en) | Methods of detecting an analyte | |
| EA201690274A1 (en) | METHOD OF SITE-SPECIFIC ENZYMATIC SWIPING OF NUCLEIC ACIDS IN VITRO INTRODUCTION NOT MEETING IN THE NATURE OF NUCLEOTIDES | |
| PE20211498A1 (en) | ANTIBODIES DIRECTED AGAINST IL-11 | |
| EP4461812A3 (en) | Method for preparing a next generation sequencing (ngs) library from a ribonucleic acid (rna) sample and compositions for practicing the same | |
| WO2008069906A3 (en) | Digital expression of gene analysis | |
| EA034770B8 (en) | Human antibodies to pd-1 | |
| MX346307B (en) | Improved process for the manufacture of 2,3,3,3-tetrafluoropropen e. | |
| NZ767927A (en) | High-throughput nucleotide library sequencing | |
| WO2008080029A3 (en) | Methods and compositions for nucleic acid amplification | |
| EA201790953A1 (en) | CHANGES IN THE EXPRESSION OF GENE IN CART-CELLS AND THEIR APPLICATION | |
| EP3351631A3 (en) | Methods for tagging dna-encoded libraries | |
| WO2008073960A3 (en) | Oligonucleotides containing high concentrations of guanine monomers | |
| DE602006012971D1 (en) | MEDIATED CHEMISTRY | |
| PE20091969A1 (en) | ANTI-PirB ANTIBODIES | |
| MA48154A1 (en) | Oligonucleotide compositions and their preparation methods | |
| EP4553171A3 (en) | Nucleic acid sequencing method | |
| ZA202110555B (en) | Improved process for preparing imetelstat | |
| EA202090282A1 (en) | COMPOSITIONS OF OLIGONUCLEOTIDES AND METHODS FOR PRODUCING THEM | |
| WO2020185681A3 (en) | Gold-mediated nucleic acid hybridization | |
| WO2011067450A3 (en) | Covalently biofunctionalized supports | |
| MX2010012061A (en) | Method for the detection of colletotrichum capsici phytopathogen fungi using the polymerase chain reaction (pcr). | |
| UA110546C2 (en) | Method for the detection of dna of bacteria chlamydia abortus, chlamydia pecorum, chlamydia psittaci in polymerase chain reaction by amplification of gene fragment encoding endoribonuclease p (rnase p rna) | |
| MX2022003615A (en) | Specific synthetic oligonucleotides for the detection of the genetic material of rickettsia rickettsii and its detection method. | |
| UA54336U (en) | method for revealing of RNA of trout hemorrhagic septicemia virus By means of polymerase chain reaction |